| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5661136 | GENZYME | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
Jan, 2018
(6 years ago) | |
|
US5661136 (Pediatric) | GENZYME | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
Jul, 2018
(5 years ago) | |
Clolar is owned by Genzyme.
Clolar contains Clofarabine.
Clolar has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Clolar are:
- US5661136
- US5661136*PED
Clolar was authorised for market use on 28 December, 2004.
Clolar is available in solution;intravenous dosage forms.
Clolar can be used as clolar is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.
The generics of Clolar are possible to be released after 14 July, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 28, 2011 |
| Pediatric Exclusivity(PED) | Jun 28, 2012 |
Drugs and Companies using CLOFARABINE ingredient
Market Authorisation Date: 28 December, 2004
Treatment: Clolar is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens
Dosage: SOLUTION;INTRAVENOUS
CLOLAR family patents
